Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves ...

ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

In immune-mediated inflammatory diseases, the overall risk for serious adverse events is not notably higher with combo ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...